share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/15 20:05
牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has announced a one-for-one hundred reverse stock split of its common stock and warrants. This corporate action was previously reported in a Form 8-K filed on May 10, 2024, and the Certificate of Amendment was filed with the Secretary of State of Texas on May 6, 2024. The reverse stock split will result in every one hundred shares of the pre-split issued and outstanding common stock being automatically converted into one post-split share. Fractional shares will be rounded up. The reverse stock split will take effect at the market open on May 17, 2024, with the common stock trading under the new CUSIP number 42254E302. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively. Adjustments will also be made to the company's outstanding warrants, with the exercise price per share of common stock attributable to the public warrants increasing to $425.00 post-split. The CUSIP for the public warrants will remain unchanged.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has announced a one-for-one hundred reverse stock split of its common stock and warrants. This corporate action was previously reported in a Form 8-K filed on May 10, 2024, and the Certificate of Amendment was filed with the Secretary of State of Texas on May 6, 2024. The reverse stock split will result in every one hundred shares of the pre-split issued and outstanding common stock being automatically converted into one post-split share. Fractional shares will be rounded up. The reverse stock split will take effect at the market open on May 17, 2024, with the common stock trading under the new CUSIP number 42254E302. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively. Adjustments will also be made to the company's outstanding warrants, with the exercise price per share of common stock attributable to the public warrants increasing to $425.00 post-split. The CUSIP for the public warrants will remain unchanged.
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 宣佈對其普通股和認股權證進行一比一的反向股票拆分。該公司訴訟此前曾在2024年5月10日提交的8-K表格中報告，修正證書於2024年5月6日提交給德克薩斯州國務卿。反向股票拆分將導致拆分前已發行和流通的普通股中每100股自動轉換爲拆分後的一股。零星股票將四捨五入。反向股票拆分將在2024年5月17日開盤時生效，普通股將以新的CUSIP編號 42254E302 進行交易。普通股和公開認股權證的交易代碼將分別保持爲 “HSCS” 和 “HSCSW”。還將對公司的未償認股權證進行調整，公開認股權證所佔普通股的每股行使價提高至425.00美元。公開認股權證的CUSIP將保持不變。
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 宣佈對其普通股和認股權證進行一比一的反向股票拆分。該公司訴訟此前曾在2024年5月10日提交的8-K表格中報告，修正證書於2024年5月6日提交給德克薩斯州國務卿。反向股票拆分將導致拆分前已發行和流通的普通股中每100股自動轉換爲拆分後的一股。零星股票將四捨五入。反向股票拆分將在2024年5月17日開盤時生效，普通股將以新的CUSIP編號 42254E302 進行交易。普通股和公開認股權證的交易代碼將分別保持爲 “HSCS” 和 “HSCSW”。還將對公司的未償認股權證進行調整，公開認股權證所佔普通股的每股行使價提高至425.00美元。公開認股權證的CUSIP將保持不變。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。